BridgeMD
A scientific study on a vaccine against HPV infection (human papilloma virus) (a vaccine for the prevention of cervical cancer and genital warts)
EU CTIS ID: 2023-508683-30-00
What this study is testing
To assess the long-term effectiveness of the 9vHPV vaccine by monitoring the combined incidence of Cervical Intraepithelial Neoplasia (CIN) 2, CIN 3, Adenocarcinoma In Situ (AIS) and cervical cancer related to HPV 16, 18, 31, 33, 45, 52, and 58 in women from Protocol V503-001 in the Nordic region vaccinated with the 9vHPV vaccine
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Randomized into the V503-001 (NCT00543543) study from a Denmark, Norway, or Sweden site and participated in the study by receiving either the selected dose formulation of the 9vHPV vaccine or GARDASIL
- Agrees to allow passive follow-up, analysis of biopsy specimens, future contact from the National Registry Study Centers, and serum collection
You likely can't join if
- There are no exclusion criteria
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.